There has been recent media coverage concerning a rare atypical femoral fracture that may be a side effect of denosumab (Prolia), an osteoporosis medication manufactured by Amgen. Osteoporosis Canada’s Scientific […]

Tools Algorithm 1 Integrated approach to the management of bone health and fracture prevention in postmenopausal females and males 50 years and older. DOWNLOAD Algorithm 2 Approach to pharmacotherapy to […]

Latest News A New Clinical Practice Guideline for management of osteoporosis and fracture prevention in Canada October 10, 2023 On October 10, 2023, a new guideline on managing osteoporosis to […]

CAROC In 2005, Osteoporosis Canada, in association with the Canadian Association of Radiologists, launched the 10-year absolute fracture risk assessment – CAROC. In addition to BMD (lowest T-score of hip […]

FRAX In addition to femoral neck (hip) BMD, age, gender, fracture history and steroid use, FRAX also takes into account other clinical risk factors to calculate the absolute 10-year risk […]

There is no excerpt because this is a protected post.

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

FRACTURE RISK ASSESSMENT Determining your risk of breaking a bone Rather than relying solely on the results of a bone mineral density (BMD) test to make treatment decisions for osteoporosis, […]